Other
Daratumumab
0
Pipeline Programs↗
5
Active Trials↗
1
Companies Involved↗
Daratumumab is an early-stage landscape with 0 programs across 1 company. The most active players are Johnson & Johnson.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
15
clinical trials
Completed7 · 47%
Active, not recruiting2 · 13%
Recruiting2 · 13%
Not yet recruiting1 · 7%
Unknown status1 · 7%
Withdrawn1 · 7%
Other1 · 7%
Clinical Trials
Trial Activity
15 trials
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Recruiting·—·Phase 2·NCT06100237·50 enrolled
Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program
Active, not recruiting·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT06253637·31 enrolled
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Not yet recruiting·—·Phase 2·NCT07485647·50 enrolled
Biomarkers of AKI in Patients Receiving Daratumumab
Completed·—·N/A·NCT06549634·20 enrolled
Daratumumab in Treatment of PGNMID and C3 GN
Completed·—·Phase 2·NCT03095118·12 enrolled
Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.
Completed·—·N/A·NCT05306587·40 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)